These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 20616600)

  • 1. Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective.
    Lee JM; Han KH
    Oncology; 2010 Jul; 78 Suppl 1():167-71. PubMed ID: 20616600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
    Kudo M; Ueshima K
    Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
    Zhang T; Ding X; Wei D; Cheng P; Su X; Liu H; Wang D; Gao H
    Anticancer Drugs; 2010 Mar; 21(3):326-32. PubMed ID: 20016366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
    Peck-Radosavljevic M; Greten TF; Lammer J; Rosmorduc O; Sangro B; Santoro A; Bolondi L
    Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):391-8. PubMed ID: 19940784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib for the treatment of unresectable hepatocellular carcinoma.
    Kane RC; Farrell AT; Madabushi R; Booth B; Chattopadhyay S; Sridhara R; Justice R; Pazdur R
    Oncologist; 2009 Jan; 14(1):95-100. PubMed ID: 19144678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib in advanced hepatocellular carcinoma.
    Llovet JM; Ricci S; Mazzaferro V; Hilgard P; Gane E; Blanc JF; de Oliveira AC; Santoro A; Raoul JL; Forner A; Schwartz M; Porta C; Zeuzem S; Bolondi L; Greten TF; Galle PR; Seitz JF; Borbath I; Häussinger D; Giannaris T; Shan M; Moscovici M; Voliotis D; Bruix J;
    N Engl J Med; 2008 Jul; 359(4):378-90. PubMed ID: 18650514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
    Boige V; Barbare JC; Rosmorduc O;
    Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The present and the future landscape of treatment of advanced hepatocellular carcinoma.
    Rimassa L; Santoro A
    Dig Liver Dis; 2010 Jul; 42 Suppl 3():S273-80. PubMed ID: 20547314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.
    Kuzuya T; Tsuchiya K; Izumi N
    Gan To Kagaku Ryoho; 2010 Oct; 37(10):1883-86. PubMed ID: 21069944
    [No Abstract]   [Full Text] [Related]  

  • 11. Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.
    Inuzuka T; Nishikawa H; Sekikawa A; Takeda H; Henmi S; Sakamoto A; Saito S; Kita R; Kimura T; Osaki Y; Kudo M
    Oncology; 2011; 81 Suppl 1():152-7. PubMed ID: 22212950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib.
    Frenette CT; Frederick RT; Gish RG
    J Clin Gastroenterol; 2011 Sep; 45(8):733-7. PubMed ID: 20930642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
    Kim HY; Park JW
    Dig Dis; 2011; 29(3):303-9. PubMed ID: 21829021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
    Kim HY; Park JW; Nam BH; Kim HK; Choi JI; Kim TH; Kim HB; Kim CM
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1612-8. PubMed ID: 21517968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
    Chaparro M; González Moreno L; Trapero-Marugán M; Medina J; Moreno-Otero R
    Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1269-77. PubMed ID: 18808443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
    J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic treatment of hepatocellular carcinoma: dawn of a new era?
    Zhu AX
    Ann Surg Oncol; 2010 May; 17(5):1247-56. PubMed ID: 20405329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.
    Kudo M
    Dig Dis; 2011; 29(3):289-302. PubMed ID: 21829020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Yau T; Pang R; Chan P; Poon RT
    Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
    Miyahara K; Nouso K; Tomoda T; Kobayashi S; Hagihara H; Kuwaki K; Toshimori J; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Yamamoto K
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1604-11. PubMed ID: 22011296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.